Marinus Pharmaceuticals (NASDAQ:MRNS) Now Covered by StockNews.com

StockNews.com began coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research report report published on Saturday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

Other equities research analysts have also issued reports about the stock. Oppenheimer raised shares of Marinus Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 target price on the stock in a report on Monday, September 23rd. Royal Bank of Canada reduced their price objective on shares of Marinus Pharmaceuticals from $3.00 to $1.00 and set a “sector perform” rating on the stock in a research note on Friday, October 25th. JMP Securities restated a “market perform” rating on shares of Marinus Pharmaceuticals in a report on Thursday, October 24th. EF Hutton Acquisition Co. I raised Marinus Pharmaceuticals to a “strong-buy” rating in a report on Monday, September 30th. Finally, TD Cowen reissued a “hold” rating on shares of Marinus Pharmaceuticals in a research note on Friday, October 25th. Nine investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $4.79.

Marinus Pharmaceuticals Trading Up 15.1 %

Shares of MRNS stock opened at $0.37 on Friday. The firm has a market capitalization of $20.50 million, a price-to-earnings ratio of -0.15 and a beta of 1.25. The business’s 50-day moving average price is $0.39 and its 200-day moving average price is $1.08. Marinus Pharmaceuticals has a 12 month low of $0.22 and a 12 month high of $11.26.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Hussman Strategic Advisors Inc. grew its stake in Marinus Pharmaceuticals by 14.3% in the second quarter. Hussman Strategic Advisors Inc. now owns 84,000 shares of the biopharmaceutical company’s stock valued at $98,000 after acquiring an additional 10,500 shares during the period. AQR Capital Management LLC lifted its holdings in shares of Marinus Pharmaceuticals by 70.3% in the 2nd quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 12,934 shares in the last quarter. Point72 DIFC Ltd acquired a new stake in Marinus Pharmaceuticals in the 2nd quarter valued at $28,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in Marinus Pharmaceuticals during the 2nd quarter valued at $64,000. Finally, World Investment Advisors LLC acquired a new position in Marinus Pharmaceuticals during the third quarter worth $104,000. 98.80% of the stock is owned by institutional investors.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.